What you should know:
1. Teva sought approval to market a generic version of Linzess, also known as linaclotide, before Ironwood and Allergan’s patents expired.
2. Ironwood and Allergan granted Teva permission to market a 145 mcg and a 290 mcg generic version of Linzess in the U.S. effective March 31, 2029. However, Teva will not be allowed to market a 72 mcg version of Linzess.
3. The lawsuit between the companies will be dismissed if the settlement is approved by the Federal Trade Commission and Department of Justice.
More articles on gastroenterology:
Cardinal surgical gown quality issues cause surgery centers to reschedule procedures
California ASC partners with ORHub
Medline acquires device distributor in Canada
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.